Latest news with #V.Mohan
Economic Times
5 days ago
- Health
- Economic Times
Novo Nordisk's Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it works
Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy contains semaglutide, mimicking a hormone to control blood sugar and reduce hunger. Priced from Rs 17,345 to Rs 26,015 monthly, it showed significant weight loss in trials. Tired of too many ads? Remove Ads India's obesity market is growing fast Tired of too many ads? Remove Ads How Wegovy Works Wegovy India Price List Dose Monthly Price (Rs) Price Per Dose (Rs) 0.25 mg Rs 17,345 Rs 4,366 0.5 mg Rs 17,345 Rs 4,366 1 mg Rs 17,345 Rs 4,366 1.75 mg Rs 24,280 Rs 6,070 2.4 mg Rs 26,015 Rs 6,503 Mounjaro Dose Monthly Price (Rs) 2.5 mg Rs 14,000 5 mg Rs 17,500 Almost like weight loss surgery, but with a catch Wegovy vs Mounjaro: What's the Difference? Feature Wegovy (Semaglutide) Mounjaro (Tirzepatide) How it works Mimics GLP-1 hormone Acts on GLP-1 and GIP hormones Effect Lowers appetite, slows digestion Improves insulin and reduces appetite Approved for Weight loss Diabetes (off-label for weight loss) How to use Weekly injection via Flexpen Weekly injection via vial Price range Rs 17,345–Rs 26,015 Rs 14,000–Rs 17,500 In a big step for India's weight loss drug market, Danish pharmaceutical company Novo Nordisk has officially launched Wegovy , its much-talked-about weight loss injection. The company is now competing directly with Eli Lilly's popular drug, Mounjaro Wegovy is a once-a-week injection that comes in a pen-like device called FlexTouch. It's easy to use and doesn't require vials or syringes. According to Managing Director of Novo Nordisk India, Vikrant Shrotriya, the drug will be available in pharmacies across India by the end of June 2025, The Times of India has one of the world's highest numbers of people struggling with weight. Around 254 million people have general obesity and over 351 million suffer from belly fat-related issues. With the anti-obesity medicine market jumping from Rs 133 crore in 2021 to Rs 576 crore today (as per PharmaTrac), Novo Nordisk sees a huge said, 'Obesity is a chronic illness and a growing problem in India. Wegovy is easy to use and will be priced specially for Indian patients.'Wegovy contains a compound called semaglutide , which mimics a natural hormone in the body. This hormone helps control blood sugar, reduce hunger, slow digestion, and make you feel full for longer. While similar drugs like Ozempic are meant for diabetes, Wegovy is approved for long-term weight comes in a FlexTouch device, allowing users to adjust their weekly dose easily. Each monthly pack includes four needles. The medicine works on brain areas that manage appetite and food to Dr V. Mohan, a well-known diabetologist, 'Semaglutide not only helps in weight loss but also improves heart and inflammation markers. It's a strong option for Indian patients dealing with both obesity and rising heart risks.'For comparison, Eli Lilly's Mounjaro is slightly cheaper:Wegovy has shown very strong results. In global studies, people lost up to 15% of their weight on average, and some even lost 20%. It also helped lower the risk of heart attacks and strokes and improved liver the results are mostly maintained only if the person continues using the drug. If stopped, weight gain can return. Doctors also warn that muscle loss may happen over time, so people need to be regularly from TOI
The Hindu
12-06-2025
- Health
- The Hindu
V. Mohan chosen for EASD Diabetes Global Impact Prize
The European Association for the Study of Diabetes (EASD)'s committee for the Diabetes Global Impact Prize has chosen V. Mohan, diabetologist and chairman, Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, as the first awardee and lecturer of the EASD Diabetes Global Impact Prize 2025. The award is in recognition of his contributions in clinical/translational research on diabetes that have had a global impact. As a part of this, Dr. Mohan will also deliver the first Diabetes Global Prize Lecture at the 61st EASD Annual Meeting scheduled to be held from September 15 to 19 at Vienna in Austria.
The Hindu
10-06-2025
- Health
- The Hindu
New ‘weight-loss' drugs have lower impact in real life compared to clinical trial results: study
A recent study done in the U.S. showed that semaglutide and tirzepatide — injectable GLP-1 drugs for obesity — produce lower weight loss in a real-world setting, than during the clinical trial, because patients discontinue treatment or use lower maintenance dosages. The results were published by researchers from the Cleveland Clinic, Ohio, U.S., in the peer-reviewed journal Obesity on June 10. Semaglutide and tirzepatide are FDA-approved medications for the treatment of type 2 diabetes and chronic weight management and are now also available in India. Hamlet Gasoyan et al accessed electronic health record data from a large health system in Ohio and Florida to identify adults with overweight or obesity without type 2 diabetes who started with injectable semaglutide or tirzepatide between 2021 and 2023. They recorded early discontinuation (within 3 months) and late discontinuation (within 3–12 months) along with weight reduction. The researchers observed that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically-meaningful weight reduction in patients on these drugs. Researchers also identified the factors associated with higher odds of achieving a weight loss of 10% or more, after one year of treatment — continuing medications or discontinuing late (vs. early), taking a high maintenance dosage, getting tirzepatide (vs. semaglutide) and were female (vs. male). Commenting on the results of the study, V. Mohan, senior diabetologist, and chairman, Dr. Mohan's Diabetes Specialties Centre, Chennai, who has initiated patients on weight-loss drugs, says: 'The findings are not surprising because in a randomised clinical trial (RCT), there is constant follow up with the participants to continue with the drug regimen. On the other hand, in the real world, especially if patients buy their own medication, they often stop the drug. Even otherwise, compliance rates in real world are much poorer than in an RCT. The bottom line is that these drugs work as long as they are taken. That is how it is with most drugs, if you stop statins, for instance, cholesterol levels go up; if you stop anti-diabetic drugs or BP drugs, the sugar and BP go up.' 'A reality check' Anoop Misra, who heads Fortis C-DOC Hospital for Diabetes and Allied Sciences in Delhi, who has also put his patients on these class of drugs, says: 'This study gives us a reality check of weight loss and blood sugar lowering effects of these drugs. It is important to note that discontinuation of such drugs is likely to be more in India, driven also by cost concerns. Non-compliance to diet and exercise are additional reasons to be considered in India which may cause lower weight loss.' 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' said Dr. Gasoyan.
Time of India
26-05-2025
- Health
- Time of India
MDRF and Russia's Almazov Centre Partner for diabetes research
Chennai: The Madras Diabetes Research Foundation ( MDRF ) has signed a research collaboration with the Almazov National Medical Research Centre , based in Saint Petersburg, Russia. The partnership will focus on developing new diagnostics and treatment strategies for diabetes, with an emphasis on Gestational Diabetes Mellitus (GDM). It will also explore emerging areas such as artificial intelligence and precision medicine in diabetes care. The memorandum of understanding (MoU) was signed by Dr. V. Mohan of MDRF and Prof. Evgeny Shlyakhto, Director General of the Almazov Centre. The agreement includes training and exchange programs for medical specialists, joint conferences, academic meetings, collaborative publications, and educational and cultural exchanges. Joint research projects on gestational diabetes have begun, involving Dr. Polina V. Popova and her team from Almazov's Endocrinology Department and Dr. Mohan's team at MDRF. The collaboration is expected to expand further in the coming months.
The Hindu
23-05-2025
- Health
- The Hindu
Madras Diabetes Research Foundation and Russia's Almazov Centre sign MoU for diabetes research
The Madras Diabetes Research Foundation (MDRF) has signed a memorandum of understanding with the Almazov National Medical Research Centre in Saint Petersburg, Russia, to advance collaborative research in diabetes care. A press release said the partnership would focus on developing new diagnostic and treatment strategies, particularly for gestational diabetes mellitus. It will also explore emerging areas such as artificial intelligence (AI) and precision medicine in diabetes management. The MoU was signed by V. Mohan, Chairman, MDRF, and Evgeny Shlyakhto, Director-General of the Almazov Centre. The agreement includes joint research projects, academic exchanges, collaborative publications, and training programmes. Dr. Mohan said: 'This collaboration reflects our shared commitment to tackling diabetes through scientific innovation and global cooperation. AI and precision medicine offer exciting possibilities to improve care.' Dr. Mohan also delivered a keynote on AI in diabetes at the 8th Saint Petersburg Medical Innovation Forum, held at the Almazov Centre. Joint research on gestational diabetes is already under way, with teams led by Polina V. Popova from Almazov and MDRF researchers, the press release added.
